Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Acute Myeloid Leukemia or Myelodysplastic Syndrome in Randomized Controlled Clinical Trials of Cancer Chemotherapy With Granulocyte Colony-Stimulating Factor: A Systematic Review
2010
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
2005
Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome
2010
Cancer treatment and survivorship statistics, 2022
2022 Standout
Advances in stem cell mobilization
2014
Molecular imaging in drug development
2008 Standout
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
2015
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Neutrophils at work
2014 Standout
Nodular Lymphocyte-Predominant Hodgkin Lymphoma
2007
Silver Nanoparticles Synthesized Using Carica papaya Leaf Extract (AgNPs-PLE) Causes Cell Cycle Arrest and Apoptosis in Human Prostate (DU145) Cancer Cells
2020 Standout
Advances in stem cell mobilization
2012
FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy
2004
Nutrition and physical activity guidelines for cancer survivors
2012 Standout
Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
2010
Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin’s lymphoma and Hodgkin’s disease
2003
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
2013
Circos: An information aesthetic for comparative genomics
2009 Standout
Depletion of M2-Like Tumor-Associated Macrophages Delays Cutaneous T-Cell Lymphoma Development In Vivo
2014
Hematopoietic Stem-Cell Transplantation
2006 Standout
Cancer treatment and survivorship statistics, 2012
2012 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma
2007
Dose-Reduced Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation for Human Immunodeficiency Virus–Associated Lymphoma: AIDS Malignancy Consortium Study 020
2007
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
The Epidemiology of Myelodysplastic Syndromes
2010
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma
2006
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
2017 Standout
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma
2011
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
Late Effects of Hodgkin’s Disease and Its Treatment
2009
Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival
2011
Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation
2007
Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation
2006
Conventional second‐line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first‐line salvage therapy regimens
2005
National estimates of the use of hematopoietic stem-cell transplantation in children with cancer in the United States
2005
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
2007
Second Primary Cancers: An Overview
2008
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Hodgkin lymphoma: 2018 update on diagnosis, risk‐stratification, and management
2018
Secondary Amenorrhea After Hodgkin’s Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin’s Lymphoma Study Group
2005
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
2012
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation
2009
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Chimeric Antigen Receptor Therapy
2018 Standout
Cancer treatment and survivorship statistics, 2016
2016 Standout
Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis
2014
Systemic cancer therapy: achievements and challenges that lie ahead
2013
Cancer treatment and survivorship statistics, 2019
2019 Standout
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
2006
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
State-of-the-Art Therapeutics: Hodgkin's Lymphoma
2005
Adult nodular lymphocyte‐predominant Hodgkin lymphoma: treatment modality utilization and survival
2018
Hodgkin's lymphoma
2003
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of Markus Sieber being referenced
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial
2002
Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group
2000
Non-Hodgkin’s Lymphoma After Primary Hodgkin’s Disease in the German Hodgkin’s Lymphoma Study Group: Incidence, Treatment, and Prognosis
2001
Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin’s Disease: A Report From the German Hodgkin’s Lymphoma Study Group
2003
Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group
2003
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
2002